Acumen Pharmaceuticals (ABOS) EPS (Basic) (2020 - 2026)
Acumen Pharmaceuticals (ABOS) reported EPS (Basic) of -$0.33 for Q1 2026, up 29.97% on a YoY basis from -$0.26 in Q1 2025, and up 18.82% sequentially from -$0.41 in Q4 2025.
Acumen Pharmaceuticals (ABOS) EPS (Basic) (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 7 years of EPS (Basic) data on file, last reported at -$0.33 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Basic) rose 29.97% year-over-year to -$0.33; the trailing twelve-month figure through Mar 2026 stood at -$1.78 (up 7.53% YoY), and the FY2025 full-year result was -$3.33, down 28.14% from the prior year.
- EPS (Basic) climbed to -$0.33 in Q1 2026, from -$0.41 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.23 in Q1 2022 to a low of -$1.26 in Q3 2022.
- A 5-year average of -$0.45 and a median of -$0.36 in 2024 frame the typical range for EPS (Basic).
- Peak annual rise in EPS (Basic) reached 99.56% in 2022, while the deepest fall reached 1133.43% in 2022.
- Tracing ABOS's EPS (Basic) over 5 years: stood at -$0.35 in 2022, then gained by 13.1% to -$0.3 in 2023, then tumbled by 101.32% to -$0.61 in 2024, then soared by 32.31% to -$0.41 in 2025, then advanced by 18.82% to -$0.33 in 2026.
- Business Quant data shows ABOS's EPS (Basic) at -$0.33 in Q1 2026, -$0.41 in Q4 2025, and -$0.43 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 0.00 |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | 0.00 |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn | 7.59 |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn | 1.55 |
| 10 | Acumen Pharmaceuticals | 137.50 Mn | 137.50 Mn | - | -0.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.33 |
| Dec 31, 2025 | -0.41 |
| Sep 30, 2025 | -0.43 |
| Jun 30, 2025 | -0.67 |
| Mar 31, 2025 | -0.48 |
| Dec 31, 2024 | -0.61 |
| Sep 30, 2024 | -0.50 |
| Jun 30, 2024 | -0.36 |
| Mar 31, 2024 | -0.25 |
| Dec 31, 2023 | -0.30 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.28 |
| Mar 31, 2023 | -0.32 |
| Dec 31, 2022 | -0.35 |
| Sep 30, 2022 | -1.26 |
| Jun 30, 2022 | -0.57 |
| Mar 31, 2022 | -0.23 |
| Dec 31, 2021 | -0.42 |
| Sep 30, 2021 | -0.10 |
| Jun 30, 2021 | -127.36 |